KRT18 and viral infectious disease: We have demonstrated that DYAI-100A85 vaccine candidate formulated as an Alhydrogel®‘85’ adjuvanted SARS-CoV-2 spike S1333–527RBD-C-tag antigen elicits strong neutralizing anti-SARS-CoV-2 IgG antibodies with protective immunity against challenge with SARS-CoV-2 live virus infection, as monitored in K18-hACE-2 transgenic C57BL/6J mice (Figure 9 and Figure 10).